Increased capillary branching contributes to angiotensin type 1 receptor blocker (ARB)-induced regression of sclerosis.

Scruggs BS, Zuo Y, Donnert E, Ma L, Bertram JF, Fogo AB
Am J Pathol. 2011 178 (4): 1891-8

PMID: 21406166 · PMCID: PMC3078453 · DOI:10.1016/j.ajpath.2010.12.029

Chronic kidney disease is characterized by progressive glomerulosclerosis and tubulointerstitial fibrosis. High-dose angiotensin type 1 receptor blocker (ARB) or angiotensin-converting enzyme inhibitor can induce regression of existing glomerulosclerosis, at least in part by decreasing matrix accumulation. However, the potential mechanisms of remodeling of capillary loops remain obscure. This study aimed to determine whether capillary branching was augmented in glomeruli with ARB-induced regression of sclerosis. Three-dimensional confocal images were assessed by graph theory analysis to explore the topology of the glomerular capillary network. Compared with normal glomeruli, glomeruli of rats with progressive sclerosis were enlarged but had a significantly reduced number of capillary segments and capillary branch points and decreased complexity of the glomerular network. In contrast, in rats with regression of sclerosis induced by ARB, glomerular enlargement was due to a significantly increased number of glomerular capillary segments and capillary branch points and restored complexity of the capillary network. These data support the theory that capillary growth contributes to regression of sclerosis and is mediated at least in part by ARB-induced increased complexity and branching of capillary segments.

Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

MeSH Terms (14)

Angiotensin II Type 1 Receptor Blockers Animals Capillaries Glomerulosclerosis, Focal Segmental Humans Imaging, Three-Dimensional Kidney Glomerulus Male Microscopy, Confocal Rats Rats, Sprague-Dawley Regression Analysis Sclerosis Treatment Outcome

Connections (2)

This publication is referenced by other Labnodes entities: